HONG KONG – Shanghai Miracogen Inc., a Chinese startup focused on developing antibody-drug conjugates (ADCs) against cancer, introduced technologies from Dutch firm Synaffix BV to co-develop a potential best-in-class ADC product. Under the licensing agreement, valued up to $125 million, Miracogen will obtain nonexclusive rights to Synaffix's Glycoconnect and Hydraspace ADC technologies for use on its next clinical candidate.